- Live fireside chat webcast on Wednesday, June
20th at 2:30 p.m. EDT -
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or
the "Company"), a Phase 3 clinical-stage pharmaceutical company
focused on the development and commercialization of novel
therapeutics to treat rare, chronic and serious inflammatory and
fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief
Executive Officer of Corbus, will participate in a fireside chat at
the JMP Securities Life Science Conference on Wednesday, June 20,
2018 at 2:30 p.m. EDT in New York, NY.
Dr. Cohen will discuss the Company's four
clinical development programs in diffuse cutaneous systemic
sclerosis ("SSc"), cystic fibrosis ("CF"), skin-predominant
dermatomyositis ("DM") and systemic lupus erythematosus ("SLE") for
lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug
that is designed to resolve chronic inflammation and halt
fibrosis.
Corbus' Phase 3 RESOLVE-1 study assessing the
efficacy and safety of lenabasum for the treatment of SSc and its
Phase 2 study of lenabasum for the treatment of SLE are currently
underway. Additionally, the Company expects to initiate its next
phase of development of lenabasum for the treatment of DM in the
second half of 2018. Corbus recently commenced its Phase 2b
multicenter, double-blinded, randomized, placebo-controlled study
of lenabasum for the treatment of CF that will enroll approximately
415 patients with CF who are at least 12 years of age and at
increased risk for pulmonary exacerbations. In support of the Phase
2b study, Corbus received a Development Award for up to $25 million
from the Cystic Fibrosis Foundation.
A live audio webcast of the fireside chat will
be accessible on the Events page of the Investors section of Corbus
website, www.corbuspharma.com, and will be archived on the
Company’s website for 90 days following the event.
About Lenabasum
Lenabasum (formerly known as anabasum) is a
synthetic, oral, small-molecule, selective cannabinoid receptor
type 2 (CB2) agonist that preferentially binds to CB2 expressed on
activated immune cells and fibroblasts. CB2 activation triggers
physiologic pathways that resolve inflammation, speed bacterial
clearance and halt fibrosis. CB2 activation also induces the
production of specialized pro-resolving lipid mediators that
activate an endogenous cascade responsible for the resolution of
inflammation and fibrosis, while reducing production of multiple
inflammatory mediators. Through activation of CB2, lenabasum also
is designed to have a direct effect on fibroblasts to halt tissue
scarring. Lenabasum is believed to induce resolution rather than
immunosuppression by triggering biological pathways to turn "off"
chronic inflammation and fibrotic processes. Lenabasum has
demonstrated promising potency in preclinical models of
inflammation and fibrosis. Preclinical and human clinical studies
have shown lenabasum to have a favorable safety, tolerability and
pharmacokinetic profile. Further, the drug has demonstrated
clinical benefit and positive impact on inflammatory and
immunological markers in Phase 2 studies in diffuse cutaneous
systemic sclerosis, dermatomyositis and cystic fibrosis.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase
3 clinical-stage pharmaceutical company focused on the development
and commercialization of novel therapeutics to treat rare, chronic,
and serious inflammatory and fibrotic diseases. The Company's lead
product candidate, lenabasum, is a novel, synthetic oral
endocannabinoid-mimetic drug designed to resolve chronic
inflammation and fibrotic processes. Lenabasum is currently being
evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis,
and systemic lupus erythematosus.
For more information, please visit
www.CorbusPharma.com and connect with the Company on Twitter,
LinkedIn, Google+ and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Investor Contacts:
Institutional Investor InquiriesTed Jenkins,
Senior Director, Investor Relations and CommunicationsCorbus
Pharmaceuticals, Inc.Phone: +1 (617) 415-7745Email:
ir@corbuspharma.com
All Other Investor InquiriesJenene ThomasJenene
Thomas Communications, LLCPhone: +1 (833) 475-8247Email:
crbp@jtcir.com
Media ContactEliza Schleifstein Scient Public
RelationsPhone: + 1 (917) 763-8106 Email: eliza@scientpr.com
Source: Corbus Pharmaceuticals Holdings, Inc.
###
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024